Skip to main content
. 2011 May 2;108(20):8491–8496. doi: 10.1073/pnas.1017091108

Fig. 5.

Fig. 5.

P2pal-18S significantly attenuates mast cell tryptase-dependent neutrophil migration and paw edema in mice. (A) Human mast cells (HMC-1) were treated with 2 mg/mL of mast cell degranulating agent 48/80 or 2% λ-carrageenan/4% kaolin. Additionally, conditioned media (CM) was harvested at 24 h and a Western blot of mast cell tryptase shows release of tryptase. (B) P2pal-18S inhibits human neutrophil chemotaxis (n = 6) to mast cell media. Human neutrophils were incubated with 1 μM P2pal-18S, or 10 μM mast cell tryptase inhibitor APC-366 and allowed to migrate 30 min toward CM from mast cells. (C) C57BL/6 mice (n = 5) were pretreated with the tryptase inhibitor APC-366 (5 mg/kg, s.c.) or vehicle (20% DMSO) and then challenged with intraplantar injection of λ-carrageenan/kaolin. (D) Mast cell-conditioned media (30 μL of λ-carrageenan/kaolin–stimulated media) was injected into the hindpaws of C57BL/6 mice treated with 10 mg/kg P2pal-18S or vehicle (n = 5). Data represent mean ± SEM. #P = 0.07, *P < 0.05, and **P < 0.005.